Molecular diagnostics

QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast

Retrieved on: 
Friday, October 21, 2022
Technology, Research, Genetics, Software, Biotechnology, Health, Data Management, Other Science, Science, Protein, DNA, RNA, Knowledge, Life, Automation, Blood, Molecular diagnostics, Solution, List of life sciences, QIAGEN, Fine chemical, Baking, Insight

Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

Key Points: 
  • Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.
  • Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.
  • QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
  • As of June 30, 2022, QIAGEN employed more than

Veterinary Diagnostics Market Report 2022: Growing Prevalence of Zoonotic Diseases to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 10, 2022
Veterinary, Health, Adoption, Veterinarian, Microbiology, Urbanization, Cat, Prevalence, Zoonosis, Growth, Diagnosis, Animal, ELISA, CAGR, APAC, Income, Medicine, Dog, Molecular diagnostics, PCR, Urine test strip, Awareness, Incidence, Hospital, USD, Livestock, Vaccine, Medical device, Pet, Technology, Cattle, Microarray, Hematology

The global veterinary diagnostics market is projected to reach USD 4.4 billion by 2027 from USD 2.8 billion in 2022, at a CAGR of 9.2%.

Key Points: 
  • The global veterinary diagnostics market is projected to reach USD 4.4 billion by 2027 from USD 2.8 billion in 2022, at a CAGR of 9.2%.
  • Based on technology, the veterinary diagnostics market is segmented into clinical biochemistry, immunodiagnostics, molecular diagnostics, hematology, urinalysis, and other veterinary diagnostic technologies (includes microbiology and histopathology tests).
  • Clinical biochemistry analyzers are more commonly adopted in veterinary diagnostic laboratories, leading to a higher share in the veterinary diagnostics market.
  • Growth in pet adoption, increasing awareness about animal health, and growing per capita animal health expenditure, especially in India and China, are contributing to the growth of the APAC veterinary diagnostics market.

EPTAM Precision and Sterling Join Forces to Become the Partner of Choice for Medical Molding Customers

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Other Manufacturing, Health, Medical Devices, Engineering, Chemicals, Plastics, Technology, Manufacturing, Molecular diagnostics, Consumer electronics, Culture, Frazier Healthcare Partners, SRL Diagnostics, LSR, Product life-cycle theory, Company, Acquisition, Medtech, Philosophy, Partnership, Defense, Automation, Albright, CEO, Â, Electronics, Solution, CA, Biopharma LLC, Family, Aerospace, Plastic, Single-use medical devices, Silicone, Medical device, 3D printing, Risk management, Sterling

Albright brings an exciting new capability into the EPTAM portfolio with their expertise in silicone injection tooling fabrication and molding.

Key Points: 
  • Albright brings an exciting new capability into the EPTAM portfolio with their expertise in silicone injection tooling fabrication and molding.
  • Founded in 1981, EPTAM is an outsourced manufacturer of medical device components, implants, single-use medical disposable, biopharma and diagnostic devices, as well as other high-precision surgical device components.
  • The Company has expertise with polymer machining, precision metal machining, injection molding, laser cutting/welding and metal injection molding, which the company targets to open later this year.
  • Founded in 1968, Sterling is a vertically integrated injection molding solutions partner in the consumer product, healthcare and defense industries.

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

Retrieved on: 
Monday, September 26, 2022
Becton, Molecular diagnostics, Health, Therapy, EUA, Laboratory, Safety, Infection, Efficiency, COVID-19, Twitter, BDX, NYSE, Becton, Dickinson and Company headquarters, FDA, Monkeypox virus, Food, Organization, LinkedIn, Company, TNA, Urinary tract infection, Monkeypox, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Human services, Public health, Solution, Research, PCR, BD, Disease, Pharmaceutical industry

FRANKLIN LAKES, N.J., Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec today announced their newly developed molecular polymerase chain reaction (PCR) assay for monkeypox virus is now commercially available globally, including in the United States, for research use only applications by laboratories.

Key Points: 
  • The teams leveraged the BD MAX System open architecture reagent suite to develop the CerTest VIASURE Monkeypox molecular research use only assay.
  • "This new test boosts capacity for monkeypox research and surveillance of this global health emergency," said Nelson Fernandes, managing director of CerTest Biotec.
  • As with all CerTest assays, the CerTest VIASURE Monkeypox virus PCR Detection RUO assay for the BD MAX System is offered in a lyophilized format.
  • CerTest Biotec is a European company established in 2002 for the development and manufacturing of in vitro diagnostic medical devices.

QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System

Retrieved on: 
Thursday, September 15, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Chlamydia trachomatis, Molecular diagnostics, QIAGEN, Real-time polymerase chain reaction, Knowledge, COVID-19, NYSE, Risk, Organic acid, Blood, QGEN, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Life, Growth, Monkeypox, EU, Patient, RSV, Certification, Viral load, Reproductive health, Stanford University v. Roche Molecular Systems, Inc., Protein, Immunodeficiency, Solution, HPV, RNA, Research, DNA, Urine, Automation, EBV, SEC, Union, Mortality, Budget, Organ transplantation, Vaccine, Insight, Academy, Chlamydia, Pharma

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.
  • The new assays support QIAGENs strategy of expanding the menu of tests available for use on the NeuMoDx 96 and 288 Molecular Systems.
  • The assay adds to the broad portfolio that QIAGEN offers to address all testing needs around monkeypox.
  • QIAGEN remains committed to responding to the COVID-19 endemic by preparing to launch a new multiple-target test: NeuMoDx FluA/FluB/RSV/SARS-CoV-2 Assay with a new dual-target SARS-CoV-2 design.

QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

Retrieved on: 
Wednesday, September 14, 2022
Biotechnology, Pharmaceutical, Health, Blood, Industry, Polymerase chain reaction, Patient, Clinical trial, U.S. Securities and Exchange Commission, Research, Large-cell lung carcinoma, Inflammation, PCR, Lists of diseases, Disease, Budget, Knowledge, NSCLC, Life, Growth, Genetics, Polymerase, KRAS, Automation, DNA, SEC, EGFR, Neurodegeneration, NYSE, Risk, FDA, QGEN, FGFR, Population, Partnership, BRAF, CEO, Tissue, Data science, Squamous cell carcinoma, PIK3CA, Drug discovery, Molecular diagnostics, Workflow, Therapy, Precision medicine, Machine learning, Biomarker, Colorectal cancer, IVD, Single-nucleotide polymorphism, Cancer, Breast cancer, Protein, Solution, CA, Diagnosis, NGS, RNA, Biotechnology, Decision-making, Neuron, Pharmaceutical industry, Fine chemical, QIAGEN, LRRK2, Illumina, Insight, Academy, Pharma

The collaboration with Neuron23 shows the rapid momentum precision medicine is gaining in disease areas outside oncology, said Jonathan Arnold, Vice President, Head of Oncology and Precision Diagnostics, at QIAGEN.

Key Points: 
  • The collaboration with Neuron23 shows the rapid momentum precision medicine is gaining in disease areas outside oncology, said Jonathan Arnold, Vice President, Head of Oncology and Precision Diagnostics, at QIAGEN.
  • This collaboration combines the leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGENs long-standing experience and global leadership in companion diagnostic development.
  • QIAGENs blood-based test will help to identify patients with Parkinsons disease who are likely to respond to Neuron23s LRRK2 inhibitor.
  • We are excited to be working with an industry leader on the first companion diagnostic developed for Parkinsons disease, said Nancy Stagliano, Ph.D., CEO of Neuron23.

Fabric Genomics Expands Leadership Team in Precision Medicine

Retrieved on: 
Wednesday, September 14, 2022
Technology, Genetics, Health Technology, Cardiology, Software, Biotechnology, Health, Data Management, Oncology, Artificial Intelligence, Molecular diagnostics, Laboratory, Algorithm, Biochemistry, Twitter, Textile, Entrepreneurship, Hofherr-Schrantz-Clayton-Shuttleworth AG, Lists of diseases, LinkedIn, Growth, Exome, COO, Industry, CEO, Genetics, Genetic testing, CLIA, Doctor of Philosophy, Genomics, Clinical professor, GeneDx, FACMG, Mayo Clinic, Multimedia, Management, Medical device, Vaccine

Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director.

Key Points: 
  • Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director.
  • View the full release here: https://www.businesswire.com/news/home/20220914005240/en/
    Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director.
  • An experienced diagnostics leader and board-certified clinical geneticist, Dr. Hofherr brings more than a decade of experience in execution and innovation in large-scale clinical genomics programs in academia and industry to Fabric Genomics.
  • Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics, and clinical diagnostics.

United States In Vitro Diagnostics Markets Report 2022-2030 Featuring Key Players - QIAGEN; F. Hoffman-La Roche; Thermo Fisher Scientific; Danaher; Illumina - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Diabetes, Pharmaceutical, Managed Care, Oncology, Biometrics, Medical Devices, Infectious Diseases, Neurology, Hospitals, Genetics, Cardiology, Biotechnology, Science, Other Science, Research, Health, QIAGEN, Danaher Corporation, CVD, COVID-19, Patient, University, Application, Degenerative disease, CDC, Ageing, Death, Lists of diseases, Genetic testing, Molecular diagnostics, Tissue, USD, Infection, Medicine, Blood, Point-of-care testing, Physician, Immunoassay, Diagnosis, IVD, POC, Center, Cardiovascular disease, Urine, Prevalence, FDA, CAGR, Population, Korea Disease Control and Prevention Agency, University of California, San Francisco, Genomics, Industry, Proteomics, Adoption, Reagent, Efficiency, Medical device, Vaccine, Pharmaceutical industry, Technology, Illumina

In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents, Instruments, Services), by Technology (Immunoassay, Molecular Diagnostics), by Application, by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents, Instruments, Services), by Technology (Immunoassay, Molecular Diagnostics), by Application, by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. in vitro diagnostics market size is expected to reach USD 36.56 billion by 2030.
  • Medical instruments that perform diagnostic tests on bio-fluids including blood, urine, and tissues are known as in vitro diagnostics (IVD).
  • The IVD tests are used to study pharmacological therapy and to identify and evaluate infectious diseases, autoimmune disorders, and a variety of medical ailments.

Veterinary Diagnostics Market worth $4.4 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, September 6, 2022
Knowledge, Research, Awareness, Hematology, Virus, POC, Adoption, Companion, USD, Incidence, Zoonosis, Intelligence, Hospital, CAGR, Blood pressure, Diabetes, Arrhythmia, Laboratory, Livestock, Idexx Laboratories, SME, Fujifilm, Parasitism, Anxiety, Immunoassay, Animal, Microbiology, Growth, Urine test strip, Thermo Fisher Scientific, Kidney, Molecular diagnostics, PCR, GEM, Randox Laboratories, Bacteria, Pet, Vaccine, Marketing, University, Technology

Based on products, the veterinary diagnostic market is segmented into consumables and instruments.

Key Points: 
  • Based on products, the veterinary diagnostic market is segmented into consumables and instruments.
  • Based on technology, the veterinary diagnostics market is segmented into clinical biochemistry, immunodiagnostics, molecular diagnostics, hematology, urinalysis, and other veterinary diagnostic technologies (includes microbiology and histopathology tests).
  • Based on animal type, the veterinary diagnostics market is segmented into companion animals and livestock.
  • Veterinary reference laboratories are the major end users in the veterinary diagnostics market, accounting for a share in 2021
    Based on end users, the global veterinary diagnostic market is segmented into veterinary reference laboratories, veterinary hospitals & clinics, point-of-care testing/in-house testing, and veterinary research institutes & universities.

Veterinary Diagnostics Market worth $4.4 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, September 6, 2022
Knowledge, Research, Awareness, Hematology, Virus, POC, Adoption, Companion, USD, Incidence, Zoonosis, Intelligence, Hospital, CAGR, Blood pressure, Diabetes, Arrhythmia, Laboratory, Livestock, Idexx Laboratories, SME, Fujifilm, Parasitism, Anxiety, Immunoassay, Animal, Microbiology, Growth, Urine test strip, Thermo Fisher Scientific, Kidney, Molecular diagnostics, PCR, GEM, Randox Laboratories, Bacteria, Pet, Vaccine, Marketing, University, Technology

Based on products, the veterinary diagnostic market is segmented into consumables and instruments.

Key Points: 
  • Based on products, the veterinary diagnostic market is segmented into consumables and instruments.
  • Based on technology, the veterinary diagnostics market is segmented into clinical biochemistry, immunodiagnostics, molecular diagnostics, hematology, urinalysis, and other veterinary diagnostic technologies (includes microbiology and histopathology tests).
  • Based on animal type, the veterinary diagnostics market is segmented into companion animals and livestock.
  • Veterinary reference laboratories are the major end users in the veterinary diagnostics market, accounting for a share in 2021
    Based on end users, the global veterinary diagnostic market is segmented into veterinary reference laboratories, veterinary hospitals & clinics, point-of-care testing/in-house testing, and veterinary research institutes & universities.